News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma
Photo of Tom Powles taken from bartscancer.london
Apr 11, 2024, 08:13

Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma

Tom Powles, Director of Barts Cancer Center, recently shared on X:

“Trial in progress: The HER2/MMAE Antibody Drug Conjugates, Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma (HER2+ve). DVs efficacy looks increased also with Immuno-oncology (IO). Toxic profile looks distinct with? Decreased skin toxicity? EAU24 results will be considered in the context of other positives first line studies.”

Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma

Source: Tom Powles/X

Antibody drug conjugates Avelumab Barts Cancer Center cancer chemotherapy Disitimab EAU24 HER2 Immuno-oncology (IO) OncoDaily Oncology pembrolizumab Skin Toxicity Tom Powles Toxic profile Trial Vedotin
Special Coverage
Dialogues
Feb 21, 2025, 11:29
HPV Self-Collection for Cervical Cancer: Dr. Kay's Insights
Science
Feb 21, 2025, 11:03
George Vlachogiannis: A growing CRC burden among younger individuals in high socio-demographic index regions
Blog
Feb 21, 2025, 11:02
Divya Sachdev: Building a future where every child, no matter where they live, has a fair chance at survival
Blog
Feb 21, 2025, 10:55
Giuseppe Curigliano: Mourning the untimely passing of Giovanni Scambia - a visionary leader in European gynecologic oncology
Blog
Feb 21, 2025, 10:45
Saurabh Zanwar: Clonal plasma cell proportion in the S-phase in multiple myeloma
Blog
Feb 21, 2025, 10:37
Cihangir Akyol: A comprehensive review on colorectal ESD outcomes by Lumir Kunovsky
Celebrities
Feb 21, 2025, 10:28
In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer
Science
Feb 21, 2025, 10:07
Elai Davicioni: Predicting Dose-Response to Prostate Cancer Radiotherapy
Blog
Feb 21, 2025, 10:00
Alexios Matikas: Adjuvant endocrine treatment strategies for non-metastatic breast cancer
Blog
Feb 21, 2025, 09:58
Miriam Mutebi: February - a whirlwind of learning, collaboration, and action
Blog
Feb 21, 2025, 09:54
The publication of the European Commission Work Programme for 2025 - ESMO
Blog
Feb 21, 2025, 09:45
Michelle Kirschner: New programming at the Cancer Survivorship Provider Network